Larazotide acetate, 神经元乙酰胆碱受体；α3/β4 部分激动剂

蛋白质

醋酸拉唑肽

F77451 | Larazotide acetate | Glycine, glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolyl-, monoacetate | UNII-FO8S2IW40N | Larazotide acetate [USAN] | DTXSID401007986 | FO8S2IW40N | D09352 | Q25327025 | Glycylglycyl-L-valyl-L-leucyl-L-valyl-L-gl

Larazotide acetate

L646246-5mg

5mg

≥98%

干燥,-80℃储存

超低温冰袋运输

Larazotide acetate is a peptide which is an orally active zonulin antagonist. Larazotide acetate shows antiviral activity to varicella-zoster virus (VZV) with EC 50 s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide acetate can be used for the research of celiac disease and infection . In Vitro Larazotide acetate (1-100 μM; 5 d) affects Vero cell growth. Larazotide acetate (1-100 μM; 3 d) shows antiviral activity to varicella-zoster virus (VZV) with EC 50 s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide acetate (1 and 3 mM; 72 h) inhibits cytokine-induced tight junction permeability in Caco-2 cells. Larazotide acetate (12.5 mM; 1 h) inhibits PTG-induced ZO-1 redistribution and actin cytoskeletal rearrangement in IEC6 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity AssayCell Line: Vero cell line Concentration: 1-100 μM Incubation Time: 5 days Result: Inhibited Vero cell growth with an CC 50 value of 82.5 μM. In Vivo Larazotide acetate (250 μg; i.p. twice a week for 7 weeks) inhibits intestinal permeability in gluten-sensitive transgenic mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: HLA-HCD4/DQ8 double transgenic miceDosage: 250 μg Administration: Intraperitoneal injection; 250 μg twice a week for 7 weeks Result: Improved barrier function parameters and reduced macrophage counts in the lamina propria to control levels. Form:Solid IC50& Target:Paracellular permeability

醋酸拉拉唑肽是一种多肽，是一种口服活性佐宁拮抗剂。醋酸拉拉唑肽对水痘-带状疱疹病毒（VZV）具有抗病毒活性，对 OKA 株和 07-1 株的 EC 50 s 分别为 44.14 和 59.06 μM。醋酸拉拉唑肽可

881851-50-9

C34H59N9O12

785.89 g/mol

44146842

CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CN.CC(=O)O

acetic acid;2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid

1S/C32H55N9O10.C2H4O2/c1-16(2)12-20(38-30(49)26(17(3)4)39-24(44)14-35-23(43)13-33)28(47)40-27(18(5)6)31(50)37-19(9-10-22(34)42)32(51)41-11-7-8-21(41)29(48)36-15-25(45)46;1-2(3)4/h16-21,26-27H,7-15,33H2,1-6H3,(H2,34,42)(H,35,43)(H,36,48)(H,37,50)(H,38,49)(H,39,44)(H,40,47)(H,45,46);1H3,(H,3,4)/t19-,20-,21-,26-,27-;/m0./s1

NYGCNONRVCGHAT-UFIKZEAMSA-N

CC(C)CC(C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)N1CCCC1C(=O)NCC(=O)O)NC(=O)C(C(C)C)NC(=O)CNC(=O)CN.CC(=O)O

44146842

H2O : 16.67 mg/mL (21.21 mM; Need ultrasonic) DMSO : 3.2 mg/mL (4.07 mM; Need ultrasonic and warming)

10

13

21

785.428 Da

785.428 Da

339.000 Ų

55

0

1320.000

0

2

部分激动剂

神经元乙酰胆碱受体；α3/β4 部分激动剂